title: Copayments: too much, yet not enough?
abstract: As more biologics aimed at larger patient populations come to market, the effectiveness and appropriateness of copayments comes into question. This classic cost-sharing tool - developed for an earlier era's less expensive products - may not work in the biotech era.
authors: Ed
authors: E
authors: Silverman